Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemo-immunotherapy vs chemotherapy in resectable locally advanced NSCLC
2018-004515-45Phase 2Active
- Sponsor
- Fundación GECP
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: pathological complete response. Started Apr 2019; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-004515-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004515-45.